Sign inJoin waitlistJoin the waitlist

Kendrith Rowland

Director of Cancer Research at Carle Health · Carle Illinois College of Medicine

Credentials: · · · ·

History

Cancer Research at Carle Health · Carle Illinois College of Medicine
Present
Carle Foundation Hospital
Present
Carle Illinois College of Medicine
Present

Rush University Medical Center
1983–1985
Internal Medicine
University of Illinois Hospital and Clinics
1980–1983
University of Illinois at the Medical Center College of Medicine
1976–1980

Research

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial…
Journal of Clinical Oncology · 2010 · 528 citations
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study
Journal of Clinical Oncology · 2005 · 398 citations
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
Journal of Clinical Oncology · 2013 · 282 citations

CL
Charles Loprinzi
30 papers
SD
Shaker Dakhil
19 papers
AJ
Aminah Jatoi
18 papers
JK
John Kugler
15 papers
PS
Philip Stella
14 papers
Alex Adjei
13 papers
PF
Patrick Flynn
13 papers
SA
Steven Alberts
13 papers
DN
Daniel Nikcevich
12 papers
Roscoe Morton
12 papers
EP
Edith Perez
11 papers
JJ
James Jett
10 papers

Grants

Carle Cancer Center NCI Community Oncology Research Program (NCORP)
National Cancer Institute · UG1
Contact PI · $20.4M · Carle Foundation
2014–2027
Carle Cancer Center Community Clinical Oncology Program
National Cancer Institute · U10
Contact PI · $11.3M · Carle Foundation
1990–2014

Clinical trials

Prostate Cancer Survivors and Exercise and Behavioral Counseling
Study director · Completed · Phase 2
University of Illinois at Urbana-Champaign
2017–2018
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Site PI · Recruiting
Alliance for Clinical Trials in Oncology
2025–2029
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2039
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030